BSE Live
Dec 26, 12:48Prev. Close
5563.80
Open Price
5563.80
Bid Price (Qty.)
5521.05 (6)
Offer Price (Qty.)
5527.80 (2)
NSE Live
Dec 26, 12:48Prev. Close
5566.00
Open Price
5539.00
Bid Price (Qty.)
5521.00 (2)
Offer Price (Qty.)
5524.00 (4)
| Balance Sheet of Alkem Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 23.91 | 23.91 | 23.91 | 23.91 | 23.91 | |
| Total Share Capital | 23.91 | 23.91 | 23.91 | 23.91 | 23.91 | |
| Reserves and Surplus | 6,256.53 | 5,441.30 | 4,861.45 | 4,368.74 | 3,575.59 | |
| Total Reserves and Surplus | 6,256.53 | 5,441.30 | 4,861.45 | 4,368.74 | 3,575.59 | |
| Total Shareholders Funds | 6,280.44 | 5,465.21 | 4,885.36 | 4,392.65 | 3,599.50 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 6.32 | 6.32 | 6.33 | 0.00 | 0.00 | |
| Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Long Term Liabilities | 56.81 | 9.23 | 9.77 | 11.29 | 2.65 | |
| Long Term Provisions | 182.50 | 141.52 | 126.03 | 81.06 | 65.97 | |
| Total Non-Current Liabilities | 245.63 | 157.07 | 142.13 | 92.35 | 68.62 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 1,203.06 | 496.64 | 541.19 | 368.23 | 350.62 | |
| Trade Payables | 812.34 | 754.09 | 818.56 | 685.24 | 466.50 | |
| Other Current Liabilities | 405.84 | 288.05 | 324.47 | 256.94 | 254.36 | |
| Short Term Provisions | 158.52 | 131.09 | 102.46 | 102.94 | 82.81 | |
| Total Current Liabilities | 2,579.76 | 1,669.87 | 1,786.68 | 1,413.35 | 1,154.29 | |
| Total Capital And Liabilities | 9,105.83 | 7,292.15 | 6,814.17 | 5,898.35 | 4,822.41 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 1,689.25 | 1,573.76 | 1,439.85 | 1,103.21 | 847.07 | |
| Intangible Assets | 147.51 | 32.62 | 31.14 | 22.42 | 27.61 | |
| Capital Work-In-Progress | 313.66 | 381.59 | 298.92 | 218.44 | 146.55 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 2,150.42 | 1,987.97 | 1,769.91 | 1,344.07 | 1,021.23 | |
| Non-Current Investments | 1,794.52 | 1,476.42 | 1,301.44 | 1,225.64 | 884.75 | |
| Deferred Tax Assets [Net] | 819.16 | 636.59 | 578.05 | 591.00 | 409.39 | |
| Long Term Loans And Advances | 33.47 | 12.73 | 107.49 | 41.76 | 138.64 | |
| Other Non-Current Assets | 79.08 | 97.76 | 123.61 | 427.85 | 289.00 | |
| Total Non-Current Assets | 4,876.65 | 4,211.47 | 3,880.50 | 3,630.32 | 2,743.01 | |
| CURRENT ASSETS | ||||||
| Current Investments | 161.52 | 219.18 | 243.06 | 292.00 | 272.92 | |
| Inventories | 1,092.58 | 991.28 | 1,024.16 | 858.76 | 590.03 | |
| Trade Receivables | 1,555.07 | 966.64 | 875.00 | 633.32 | 480.44 | |
| Cash And Cash Equivalents | 765.61 | 397.94 | 278.30 | 199.06 | 524.03 | |
| Short Term Loans And Advances | 23.39 | 26.25 | 34.38 | 24.70 | 8.20 | |
| OtherCurrentAssets | 631.01 | 479.39 | 478.77 | 260.19 | 203.78 | |
| Total Current Assets | 4,229.18 | 3,080.68 | 2,933.67 | 2,268.03 | 2,079.40 | |
| Total Assets | 9,105.83 | 7,292.15 | 6,814.17 | 5,898.35 | 4,822.41 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 329.70 | 406.92 | 374.09 | 452.60 | 457.75 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 248.29 | 210.50 | 210.25 | 190.32 | 147.14 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | -- | -- | -- | |
| Other Earnings | 1,606.12 | 1,223.77 | 1,125.88 | 841.00 | 656.33 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 11.96 | 11.96 | 11.96 | 11.96 | 11.96 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | 153.04 | 243.81 | 184.30 | |
| Non-Current Investments Unquoted Book Value | 32.45 | 39.27 | 1,148.40 | 997.42 | 700.45 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | 17.66 | 15.59 | 0.01 | |
| Current Investments Unquoted Book Value | 146.81 | 201.15 | 225.40 | 276.41 | 194.41 |
04.12.2025
Alkem Lab Consolidated September 2025 Net Sales at Rs 4,000.99 crore, up 17.17% Y-o-Y
24.11.2025
Alkem Lab Standalone September 2025 Net Sales at Rs 2,542.03 crore, down 11.49% Y-o-Y
10.09.2025
Alkem Lab Standalone June 2025 Net Sales at Rs 2,372.17 crore, down 5.12% Y-o-Y
12.08.2025
Q1 Results impact: Alkem Labs, PN Gadgil shares rally up to 10% on strong earnings, Granules up 4%
12.07.2023
Alkem Laboratories Q1 PAT seen up 135.1% YoY to Rs 299.7 cr: Nirmal Bang
17.10.2018
Alkem Labs Q2 PAT may dip 30.2% YoY to Rs. 220 cr: HDFC Securities
20.04.2018
Alkem Labs Q4 PAT may dip 1.5% YoY to Rs. 130 cr: HDFC Securities
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key